Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 378,376	$ 376,727
Accounts receivable, net of allowances of $33.9 million and $28.6 million at March 31, 2014 and December 31, 2013, respectively	104,375	101,587
Inventory	86,001	87,105
Deferred tax assets	13,430	13,431
Prepaid expenses and other current assets	13,506	12,591
Total current assets	595,688	591,441
Fixed assets, net	41,390	39,268
Intangible assets, net	829,635	836,273
Goodwill	257,789	257,694
Restricted cash	1,491	1,574
Other assets	14,702	15,032
Total assets	1,740,695	1,741,282
Current liabilities:
Accounts payable	7,336	26,911
Accrued expenses	147,207	142,290
Deferred revenue	2,217	5,052
Total current liabilities	156,760	174,253
Contingent purchase price	304,627	302,363
Deferred tax liabilities	128,630	128,677
Convertible senior notes (due 2017)	238,683	236,088
Other liabilities	7,344	7,740
Total liabilities	836,044	849,121
Stockholders' equity:
Preferred stock, $1.00 par value per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value per share, 125,000,000 shares authorized; 67,205,726 issued and 65,012,744 outstanding at March 31, 2014 and 66,590,875 issued and 64,397,893 outstanding at December 31, 2013, respectively	67	66
Additional paid-in capital	1,009,605	991,982
Treasury stock, at cost; 2,192,982 shares at March 31, 2014 and December 31, 2013, respectively	(50,000)	(50,000)
Accumulated deficit	(49,895)	(44,899)
Accumulated other comprehensive loss	(4,781)	(4,652)
Total The Medicines Company stockholders' equity	904,996	892,497
Non-controlling interest in joint venture	(345)	(336)
Total stockholders' equity	904,651	892,161
Total liabilities and stockholders' equity	$ 1,740,695	$ 1,741,282